Quick Answer
Intellia Therapeutics, Inc. reported Research And Development Expense of $388.86 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed a decrease of -16.6% in Research And Development Expense from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $1.37 million | Q2 2015: $1.97 million | Q3 2015: $3.46 million | Q4 2015: $4.38 million | Q1 2016: $5.23 million | Q2 2016: $7.42 million | Q3 2016: $7.86 million | Q4 2016: $11.33 million | Q1 2017: $13.43 million | Q2 2017: $15.57 million | Q3 2017: $17.48 million | Q4 2017: $21.17 million | Q1 2018: $22.49 million | Q2 2018: $23.47 million | Q3 2018: $23.24 million | Q4 2018: $19.92 million | Q1 2019: $23.71 million | Q2 2019: $25.46 million | Q3 2019: $27.51 million | Q4 2019: $31.73 million | Q1 2020: $34.65 million | Q2 2020: $37.77 million | Q3 2020: $39.76 million | Q4 2020: $38.23 million | Q1 2021: $39.28 million | Q2 2021: $58.88 million | Q3 2021: $60.49 million | Q1 2022: $133.10 million | Q2 2022: $90.20 million | Q3 2022: $96.65 million | Q1 2023: $97.12 million | Q2 2023: $115.28 million | Q3 2023: $113.70 million | Q1 2024: $111.85 million | Q2 2024: $114.21 million | Q3 2024: $123.38 million | Q1 2025: $108.43 million | Q2 2025: $97.04 million | Q3 2025: $94.75 million.
- Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Research And Development Expense has grown by 3,381.3%.
- Historical annual values: Fiscal year 2025: $388.86 million | Fiscal year 2024: $466.31 million | Fiscal year 2023: $435.07 million | Fiscal year 2022: $419.98 million | Fiscal year 2021: $229.81 million | Fiscal year 2020: $150.41 million | Fiscal year 2019: $108.41 million | Fiscal year 2018: $89.12 million | Fiscal year 2017: $67.65 million | Fiscal year 2016: $31.84 million | Fiscal year 2015: $11.17 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: